Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: \>=20 years
Sex: Either male or female
Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be \>= 150 mmHg and \>= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.
You may not be if
Malignant hypertension
Renovascular hypertension
Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
Symptoms of cerebrovascular disorder
Serious hepatic dysfunction
Renal function disorder (serum creatinine \>= 4.0 mg/dL)
Known hypersensitivity to angiotensin II receptor antagonists
Hyperkalaemia (potassium \>= 5.5 milliequivalents per liter (mEq/L))
Treatment with the other investigational drug within 6 months of initiation of the present study
Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
Previous treatment with the trial medication of the present study
Otherwise judged ineligible by the investigator
Clareo Health | Pharmacokinetics of BIBR 277 in Hypertensive Patients
